Accès gratuit
Numéro
Med Sci (Paris)
Volume 25, Numéro 12, Décembre 2009
Anticorps monoclonaux en thérapeutique
Page(s) 1163 - 1168
Section III - Un futur en développement
DOI https://doi.org/10.1051/medsci/200925121163
Publié en ligne 15 décembre 2009
  1. LEEM Biotech et Genopole. Bioproduction 2008, état des lieux et recommandations pour l’attractivité de la France. Rapport de synthèse, 2008.
  2. Cochet O, Chartrain M. Les systèmes mammaliens de production actuels qui sont agréés. Med Sci (Paris) 2009; 25 : 1078–83.
  3. Kelley B. Very large scale monoclonal antibody purification : the case for conventional unit operations. Biotechnol Prog 2007; 23 : 995–1008.
  4. Beck A, Wagner-Rousset E, Bussat MC, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and fc-fusion proteins. Curr Pharm Biotechnol 2008; 9 : 482–501.
  5. Shinkawa T, Nakamura K, Yamane N, et al. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 278 : 3466–73.
  6. Arbabi-Ghahroudi M, Tanha J, MacKenzie R. Prokaryotic expression of antibodies. Cancer Metast Rev 2005; 24 : 501–19.
  7. Harmsen MM, de Haard HJ. Properties, production and applications of camelid single chain antibodies fragments. Appl Microbiol Biotechnol 2007; 77 : 13–22.
  8. Gerngross TU. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 2004; 22 : 1409–14.
  9. Ogunjimi AA, Chandler JM, Gooding CM, et al. High-level secretory expression of immunologically active intact antibody from the yeast Pichia pastoris. Biotechnol Lett 1999; 21 : 561–7.
  10. Ward M, Lin C, Victoria DC, et al. Characterization of humanized antibodies secreted by Aspergillus niger. Appl Environ Microbiol 2004; 70 : 2567–76.
  11. Jigami Y. Yeast glycobiology and its application. Biosci Biotechnol Biochem 2008; 72 : 637–48.
  12. Hamilton SR, Gerngross TU. Glycosylation engineering in yeast : the advent of fully humanized yeast. Curr Opin Biotechnol 2007; 18 : 387–92.
  13. Maras M, De Bruyn A, Vervecken W, et al. In vivo synthesis of complex N-glycans by expression of human N-acetylglucosaminyltransferase I in the filamentous fungus Trichoderma reesei. FEBS Lett 1999; 452 : 365–70.
  14. Edelman L, Margaritte C, Chaabihi H, et al. Obtaining a functional recombinant anti-rhesus (D) antibody using the baculovirus-insect cell expression system. Immunology 1997; 9 : 13–9.
  15. Altmann F, Staudacher E, Wilson IB, März L. Insect cells as hosts for the expression of recombinant glycoproteins. Glycoconj J 1999; 16 : 109–23.
  16. Hsu TA, Takahashi N, Tsukamoto Y, et al. Differential N-glycan patterns of secreted and intracellular IgG produced in Trichoplusia ni cells. J Biol Chem 1997; 272 : 9062–70.
  17. Harrison RL, Jarvis DL. Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce “mammalianized” recombinant glycoproteins. Adv Virus Res 2006; 68 : 159–91.
  18. O’Connell KP, Kovaleva E, Campbell JH, et al. Production of a recombinant antibody fragment in whole insect larvae. Mol Biotechnol 2007; 36 : 44–51.
  19. Floss DM, Falkenburg D, Conrad U. Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants : an overview. Transgenic Res 2007; 16 : 315–32.
  20. Gomord V, Chamberlain P, Jefferis R, et al. Biopharmaceutical production in plants : problems, solutions and opportunities. Trends Biotechnol 2005; 23 : 559–65.
  21. Frey AD, Karg SR, Kallio PT. Expression of rat beta(1,4)-N-acetylglucosaminyltransferase III in Nicotiana tabacum remodels the plant-specific N-glycosylation. Plant Biotechnol J 2009; 7 : 33–48.
  22. Vézina LP, Faye L, Lerouge P, et al. Transient co-expression for fast and high-yield production of antibodies with human-like N-glycans in plants. Plant Biotechnol J 2009; 7 : 442–55.
  23. Hellwig S, Drossard J, Twyman RM, et al. Plant cell cultures for the production of recombinant proteins. Nat Biotechnol 2004; 22 : 1415–22.
  24. Cadoret JP, Bardor M, Lerouge P, et al. Microalgae as cell factories producing recombinant commercial proteins. Med Sci (Paris) 2008; 24 : 375–82.
  25. Cox KM, Sterling JD, Regan JT, et al. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 2006; 24 : 1591–7.
  26. Schuster M, Jost W, Mudde GC, et al. In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system. Biotechnol J 2007; 2 : 700–8.
  27. Houdebine LM. Production of pharmaceutical proteins by transgenic animals. Comp Immunol Microbiol Infect Dis 2008. Epub Feb 1.
  28. Tang B, Yu S, Zheng M, et al. High level expression of a functional human/mouse chimeric anti-CD20 monoclonal antibody in milk of transgenic mice. Transgenic Res 2008; 17 : 727–32.
  29. Raju TS, Briggs JB, Borge SM, et al. Species-specific variation in glycosylation of IgG : evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein therapeutics. Glycobiology 2000; 10 : 477–86.
  30. Zhu L, van de Lavoir MC, Albanese J, et al. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 2005; 23 : 1159–69.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.